Insider Purchases: Inside the Buy
Tag: Growth Stocks
🛵 The Local Commerce Media Machine: Auditing DoorDash's $100M Insider Moat and the 33% Top-Line AI Acceleration
DoorDash may be building something much larger than a delivery app. With 33% revenue growth, improving profitability, a $100 million insider purchase, and potential AI commerce advantages, DASH remains one of the most fascinating platform stories in tech.
🐋 StepStone Group (STEP): The $885B Private Market Juggernaut and the Great GAAP Optical Illusion
StepStone Group may be one of Wall Street's most misunderstood asset managers. Record fee-related earnings, $40 billion in dry powder, and a massive push into private wealth suggest the future may look brighter than headline GAAP losses imply.
⚛️ Quantinuum (QNT): The $1.6B Quantum Leap, Insiders Loading at $60, and the Multiverse of Single-Digit Sales
Quantinuum's blockbuster IPO and $24 million insider-buying wave highlight the enormous promise—and equally enormous risks—of quantum computing. Revolutionary science, massive losses, and moonshot ambitions make QNT one of the market's most fascinating speculative bets.
🚀 Robinhood (HOOD): The $35M Insider Bet, the Great Wealth Transfer, and the Price of Fintech Dominance
Robinhood has evolved far beyond a commission-free trading app. With $307 billion in platform assets, 4.3 million Gold subscribers, and a $35 million insider purchase from fintech legend Meyer Malka, the company is increasingly positioning itself at the center of the next generation's financial lives.
🌐 Globant (GLOB): The AI Infrastructure Tollbooth Trading at 7x Earnings
Globant (NYSE: GLOB) may be one of the most intriguing AI-related value plays on the market. Trading 87% below its peak, the company combines a growing AI-native services platform, accelerating cash flow, aggressive share buybacks, institutional ownership above 100% of float, and a historic first insider purchase from former Hong Kong Exchange CEO Alejandro Aguzin. Is Wall Street missing the story?
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.
📈 Hamilton Lane (HLNE): The Toll Booth on a Trillion-Dollar Private Markets Highway
Hamilton Lane (HLNE) may be one of the most attractive alternative asset managers on the market today. Massive insider buying, a growing dividend, a trillion-dollar asset footprint, and expanding private-wealth opportunities combine to create a compelling long-term investment story.
⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip
Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.
☕ Black Rock Coffee Bar (BRCB): The Hypergrowth Coffee Chain Wall Street May Have Oversold
Black Rock Coffee Bar (NASDAQ: BRCB) may be one of the market’s more fascinating small-cap growth stories hiding beneath a brutal selloff. With insider buying accelerating, revenue climbing nearly 24%, and profitability improving, investors are beginning to wonder whether Wall Street overshot the downside.